Table 1.
Inventory of possible approaches to estimating and reporting GFR, attributes, and challenges
| Approach | Acronym | Race Includeda | Challenges by Attributeb,c | |||||
|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | |||
| Creatinine used as biomarker | ||||||||
| 1. CKD-EPI eGFRcr (age, sex, race)6 | CKD-EPIcr | ✓ ©® | * | * | * | * | ** | ** |
| 2. MDRD Study (age, sex, race)7 | MDRDcr | ✓ ©® | * | * | ** | * | ** | ** |
| 3. eGFRcr (CKD-EPI) (age, sex, race) with “Black” estimate reported as “high muscle mass” and non-Black estimate reported as “low muscle mass” | CKD-EPIcr_MM | ✓ © | * | ** | * | *** | *** | *** |
| 4. eGFRcr (CKD-EPI) (age, sex, race) with “Black” estimate reported as “high value” and non-Black reported as “low value” | CKD-EPIcr_H/L | ✓ © | * | ** | * | ** | *** | ** |
| 5. eGFRcr (CKD-EPI) (age, sex, race) with the Black coefficient removed and eGFR value for non-Black is reported for all | CKD-EPIcr_NB | ✓ © | * | * | * | ** | **/*** | ** |
| 6. eGFRcr (CKD-EPI) (age, sex, race), with the Black coefficient used and eGFR value for Black individuals is reported for all | CKD-EPIcr_B | ✓ © | * | * | * | ** | **/*** | ** |
| 7. Blended eGFRcr (CKD-EPI) (age, sex, race) using single coefficient weighted for percentage Black individuals in specific population reported for all | CKD-EPIcr_blend | ✓ © | * | *** | * | *** | *** | *** |
| 8. CG estimated creatinine clearance (age, sex, weight)8 | CG_Clcr | * | *** | *** | *** | *** | *** | |
| 9. eGFRcr (FAS) (age, sex, population-specific Scr/Q)43 | FAScr | * | *** | *** | *** | *** | *** | |
| 10. eGFRcr (EKFC) (age, sex, population-specific Scr/Q)27 | EKFCcr | * | *** | *** | *** | *** | *** | |
| 11. eGFR (LM) (age, sex)44 | LMcr | * | ** | *** | *** | *** | *** | |
| 12. eGFRcr (CKD-EPI) refit without race variable38 | CKD-EPIcr_R | * | * | * | * | * | * | |
| 13. eGFRcr (CKD-EPI) refit with height and weight without race variable45 | CKD-EPI_R_HW | * | *** | * | *** | *** | *** | |
| Creatinine in combination with cystatin C or other markers | ||||||||
| 14. eGFRcr-cys (CKD-EPI) with race coefficient (age, sex, race)46 | CKD-EPIcr-cys | ✓ ©® | ** | * | * | * | * | * |
| 15. eGFRcr-cys (CKD-EPI) (age, sex, race) with “Black” estimate reported as “high muscle mass” and non-Black estimate reported as “low muscle mass” | CKD-EPIcr-cys_MM | ✓ © | ** | ** | * | *** | *** | *** |
| 16. eGFRcr-cys (CKD-EPI) (age, sex, race) with “Black” estimate reported as “high value” and non-Black estimate reported as “low value” | CKD-EPIcr-cys_H/L | ✓ © | ** | ** | * | *** | * | * |
| 17. eGFRcr-cys (CKD-EPI) (age, sex, race) with the Black coefficient removed and value for non-Black estimate reported for all | CKD-EPIcr-cys_NB | ✓ © | ** | * | * | * | ** | ** |
| 18. eGFRcr-cys (CKD-EPI) (age, sex, race), with Black coefficient used and value for Black reported for all | CKD-EPIcr-cys_B | ✓ © | ** | * | * | ** | ** | ** |
| 19. Blended eGFRcr-cys (CKD-EPI) (age, sex, race), using a single coefficient weighted for percentage of Black patients in the specific population, is reported for all | CKD-EPIcr-cys_blend | ✓ © | ** | *** | * | *** | *** | *** |
| 20. eGFRcr-cys (CKD-EPI) refit without race variable38 | CKD-EPIcr-cys_R | ** | * | * | * | * | * | |
| 21. eGFRcr-cys (FAS) (age, sex, population-specific Q)47 | FAScr-cys | ** | *** | *** | *** | *** | *** | |
| 22. eGFRcr-cys-β2m-βtp (age, sex)48 | CKD-EPI_4M | *** | *** | * | ** | ** | ** | |
| Cystatin C or other filtration Markers | ||||||||
| 23. eGFRcys (CKD-EPI) (age, sex)49 | CKD-EPIcys | ** | ** | * | ** | * | * | |
| 24. eGFRcys (FAS) (age, sex, population-specific Q)47 | FAScys | ** | *** | *** | *** | *** | *** | |
| 25. eGFRcys (CAPA) (age, sex)50 | CAPAcys | ** | ** | *** | *** | *** | *** | |
| 26. eGFRcys-β2m-βtp (age, sex)48 | CKD-EPI_3M | *** | *** | * | ** | ** | ** | |
eGFRcr, eGFR computed using creatinine; CG, Cockcroft and Gault; FAS, full age spectrum; Scr, serum creatinine; Q, Q factor coefficient; EKFC, European Kidney Function Consortium; LM, Lund–Malmö; eGFRcr-cys, eGFR computed using creatinine and cystatin C; β2m, β2-microglobulin assay; βtp, β-trace protein; eGFRcys, eGFR computed with cystatin C; CAPA, Caucasian, Asian, pediatric, and adult.
✓ Race included in calculation © or reporting ® of equation.
For details of origin of attributes, see Delgado et al. 1 For details on basis for categorization, please see Supplemental Appendices 1–3.
Attributes are labeled as follows: 1, filtration marker assay; 2, implementation challenges; 3, equation population diversity; 4, equation performance; 5, consequences; 6, patient centeredness. For the difficulties assessment, * represents minimal challenges, ** represents some challenges, and *** represents many challenges; **/*** represents no consensus among Task Force members between some and many challenges.